licensing_iconLicensing

In addition to helping clients secure protection for their own intellectual property, BSKB represents companies looking to license intellectual property rights to others to expand markets for their goods and services or to obtain licenses from others for more freedom to sell a broader range of goods or services. BSKB also assists clients who look to cross-license intellectual property rights to create joint cooperation agreements with other companies or, as part of a more complex litigation scenario, to settle disputes with other companies.

BSKB provides legal opinions for both prospective licensors and licensees to ensure companies can move forward with licensing and acquisition plans with confidence in the value of the related intellectual property. BSKB also assists clients with an inventory and valuation of intellectual property rights and identifying and targeting potential licensing targets, as well as drafting simple to highly complex intellectual property licensing agreements.

 

Attorneys and Professionals

  • Richard Anderson

    D. Richard Anderson

    Partner

    View
  • Charles Gorenstein

    Charles Gorenstein

    Senior Counsel

    View
  • Hyuk Jung Kwon

    Hyuk Jung Kwon

    Associate

    View
  • Michael Mutter

    Michael K. Mutter

    Senior Counsel

    View
  • Jun Nakamara

    Jun (Atsushi) Nakamura

    Registered Patent Agent

    View
  • Whitney Remily

    Whitney Remily

    Of Counsel

    View

Related Articles

  • April 29, 2022

    Responding to Examiner Rejections in Chem/Pharma/Bio Applications

    by Chad M. Rink and Briana Barron | Patent Law Institute

    BSKB’s Chad Rink recently co-lectured with Briana Barron during the 2022 Patent Law Institute (PLI) virtual meeting. Their topic was “Responding to Examiner Rejections in Chem/Pharma/Bio Applications.” Chad and Briana discussed recent court decisions covering written description, obviousness, and inequitable conduct.

  • April 26, 2022

    Label Ruling Upends Generic Medicine Makers

    by MaryAnne Armstrong | WIPR

    The effects of the ‘skinny label’ decision are being felt across pharma. MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch revisits GSK v Teva.

View All Articles

Recent News

  • March 1, 2022

    Skyla A. Duncan-Jules, PhD joins BSKB

    Birch, Stewart, Kolasch & Birch, LLP (BSKB) is pleased to welcome Skyla A. Duncan-Jules, Ph.D. to the firm’s prosecution practice as a Technical Advisor in the Chemical and Life Sciences/Biotech departments.

  • January 1, 2022

    Seth S. Kim Promoted to Partner

    BSKB is pleased to announce that Seth S. Kim has been promoted to Partner of the firm.

View All News

Contact Us